SAFC and Pfenex have agreed to a partnership to produce therapeutic proteins and vaccine components for their joint clients. Pfenex will be responsible for engineering bacterial strains and developing production processes that can be transferred to SAFC's GMP fermentation facilities in Jerusalem ( Download Jerusalem-insert) for scale up and manufacturing.
The strategic partnership will focus on identifying customers seeking the total solution, from the design and engineering of a robust production strain, process development, scale up and GMP production. SAFC will subsidize a portion of upfront costs in return for the a commitment to use its GMP manufacturing services. See Outsourcing Pharma.
Posted by Bruce Lehr June 8th 2011.